ReGEV Bio
RNA-Based Gene Regulation for Climate-Resilient Crops
Company Overview
Snapshot
Founded in January 2022, ReGEV Bio operates with 1–10 employees. The company has secured funding across one round from one investor. In January 2022, ReGEV Bio received its initial funding from AgChimedes Group, marking a key milestone in its development.
Business overview
ReGEV Bio is a biotechnology company focused on enhancing plant resilience and productivity through RNA interference (RNAi) technology. This approach allows for the transient adjustment of gene expression to improve crop adaptation to environmental stresses without permanent genetic modifications. The company provides tools to farmers and the seed industry, operating within the Agriculture & Food Technologies sector, specifically targeting the Ag Tech and Sustainable Farming categories.
Company Intelligence Q&A
- What is ReGEV Bio's core technology?
- ReGEV Bio utilizes RNA interference (RNAi) technology to transiently adjust gene expression in plants, aiming to enhance resilience and productivity without permanent genetic modifications.
- When was ReGEV Bio founded?
- ReGEV Bio was founded in January 2022.
- What is ReGEV Bio's primary focus?
- ReGEV Bio focuses on improving crop adaptation to environmental stresses and optimizing existing crop varieties in response to climate challenges.
- Which group is ReGEV Bio part of?
- ReGEV Bio is an AgChimedes Group company.
- What markets does ReGEV Bio serve?
- ReGEV Bio serves farmers and the seed industry by providing tools to optimize crop varieties.